top of page
LATEST NEWS
What RMAT Designation Actually Means for a Gene Therapy
RMAT shows up in headline after headline. Here is what the FDA designation requires, what it gives developers, and the one thing it does not mean.
2 hours ago3 min read


FDA Grants RMAT to Kamau's Sickle Cell Therapy That Corrects the Mutation Itself
Nula-cel repairs the sickle mutation in a patient's own stem cells rather than switching on fetal hemoglobin. All three patients on the optimized process are transfusion-free with no pain crises.
1 day ago3 min read


A Cancer-Killing Virus Cut Bladder Cancer Recurrence by 68% in a Phase 3 Trial
CG Oncology's cretostimogene reduced the risk of recurrence by 68% versus surveillance in 367 patients with intermediate-risk bladder cancer, with no serious treatment-related side effects.
2 days ago3 min read


LEARN MORE
LEARN MORE

GENE TECH TIMES
The Future Has Arrived


What RMAT Designation Actually Means for a Gene Therapy
RMAT shows up in headline after headline. Here is what the FDA designation requires, what it gives developers, and the one thing it does not mean.
2 hours ago


FDA Grants RMAT to Kamau's Sickle Cell Therapy That Corrects the Mutation Itself
Nula-cel repairs the sickle mutation in a patient's own stem cells rather than switching on fetal hemoglobin. All three patients on the optimized process are transfusion-free with no pain crises.
1 day ago


A Cancer-Killing Virus Cut Bladder Cancer Recurrence by 68% in a Phase 3 Trial
CG Oncology's cretostimogene reduced the risk of recurrence by 68% versus surveillance in 367 patients with intermediate-risk bladder cancer, with no serious treatment-related side effects.
2 days ago


Four Years After One Infusion, a Gene Therapy Keeps Crigler-Najjar Syndrome in Check
In NEJM, Généthon's AAV gene therapy GNT0003 kept bilirubin below toxic levels for four years in all three patients at the therapeutic dose, and two stopped daily phototherapy.
3 days ago


Lexeo's One-Time Gene Therapy Cut Dangerous Heart Rhythms by 80% in PKP2 Heart Disease
Interim Phase I/II results for Lexeo's LX2020 show an 80% average drop in dangerous heart-rhythm runs at the higher dose, with heart biopsies showing the missing PKP2 protein restored. The FDA is open to a faster approval path.
4 days ago
bottom of page


